Aadi Bioscience, Inc. (AADI)
After hours:
| Previous close | 1.8000 |
| Open | 1.7800 |
| Bid | 1.8200 x 400 |
| Ask | 1.8700 x 100 |
| Day's range | 1.7800 - 1.8500 |
| 52-week range | 1.5500 - 8.6000 |
| Volume | |
| Avg. volume | 351,373 |
| Market cap | 45.18M |
| Beta (5Y monthly) | 0.30 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.4400 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 11.67 |
PR NewswireAadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced it will present new non-clinical data that highlight the combinability of nab-sirolimus and its potential for synergy to enhance anti-cancer effects and overcome resistance. These data will be presented during poster sessions at the American Association for Cancer Research (AACR) Annual Meeting in
- PR Newswire
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)
Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage precision oncology company focused on developing and commercializing therapies for cancers with alterations in the mTOR pathway, today announced patients in the AMPECT trial whose malignant perivascular epithelioid cell tumor (PEComa) had gynecologic origins experienced efficacy and safety consistent with the overall study population. The AMPECT trial formed the basis for the FDA approval of the company's nab-sirolimus, FYARRO®, for advanc
Simply Wall St.Aadi Bioscience Full Year 2023 Earnings: US$2.44 loss per share (vs US$2.69 loss in FY 2022)
Aadi Bioscience ( NASDAQ:AADI ) Full Year 2023 Results Key Financial Results Revenue: US$24.4m (up 60% from FY 2022...
